Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$333.45 USD

333.45
331,765

-0.35 (-0.10%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $334.83 +1.38 (0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 25% (190 out of 252)

Industry: Medical Services

Better trading starts here.

Zacks News

Zacks.com featured highlights Medpace, American Axle, Diebold Nixdorf, Euronet and Omnicom

Medpace, American Axle, Diebold Nixdorf, Euronet and Omnicom have been highlighted in this Screen of The Week article.

3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)

Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

QIAGEN (QGEN) to Enhance Forensics With New Partnership

QIAGEN's (QGEN) recent deal advances a novel test for its QIAcuity digital PCR devices. This will enhance forensics by improving the quantification of DNA in human samples.

Insulet (PODD) Q1 Earnings Top, 2024 Revenue View Raised

Insulet's (PODD) first-quarter performance benefits from the continued high demand for Omnipod 5.

Swayta Shah headshot

5 Stocks With Upgraded Broker Ratings Worth Investing in Now

Brokers have deeper insights into stocks and macroeconomic factors. So, one should follow broker rating upgrades to pick stocks like Medpace (MEDP), American Axle & Manufacturing (AXL), Diebold Nixdorf (DBD), Euronet (EEFT) and Omnicom (OMC).

Haemonetics (HAE) Q4 Earnings Top Estimates, Margins Expand

Haemonetics (HAE) Q4 revenues were driven by an uptick in the Plasma and Hospital segments.

Are Medical Stocks Lagging Medpace (MEDP) This Year?

Here is how Medpace (MEDP) and Tenet Healthcare (THC) have performed compared to their sector so far this year.

STERIS (STE) Q4 Earnings Match Estimates, Margins Contract

STERIS' (STE) fourth-quarter performance in AST is dented by a decline in capital equipment revenues. The contraction of margins is concerning.

Charles River (CRL) Q1 Earnings & Revenues Beat, Fall Y/Y

Charles River's (CRL) Manufacturing and RMS business segments report organic revenue growth.

Exact Sciences (EXAS) Q1 Revenues Rise Y/Y, Gross Margin Down

Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences' (EXAS) first-quarter top line.

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

Investors are optimistic about Labcorp (LH), led by strategic acquisitions and strong expansion in the Biopharma Laboratory.

Medpace Holdings, Inc. (MEDP) Is a Trending Stock: Facts to Know Before Betting on It

Medpace (MEDP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down

Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1

Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in revenue cycle management.

Penumbra (PEN) Q1 Earnings Lag Estimates, Margins Expand

Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.

Nalak Das headshot

5 Growth Stocks to Buy for Steady Returns in May

We have narrowed our search to five growth stocks that have solid upside left for 2024. These stocks are NFLX, WING, PATH, SKX and MEDP.

Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View

Veracyte's (VCYT) first-quarter 2024 performance reflects the strength of its testing business.

Globus Medical (GMED) Q1 Earnings Top Estimates, Margins Fall

Globus Medical (GMED) delivers massive sales and earnings growth in the first quarter of 2024.

Henry Schein (HSIC) Tops Q1 Earnings, Lowers '24 Sales View

Henry Schein's (HSIC) first-quarter performance reflects a strong recovery from last year's cyber incident.

Omnicell (OMCL) Q1 Earnings Top Estimates, Revenues Down Y/Y

Omnicell (OMCL) outpaces expectations in the first quarter of 2024 in a challenging customer environment.

Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens

Illumina (ILMN) surpasses expectations in the first quarter in a challenging global macroeconomic environment.

Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View

Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.

Brokers Suggest Investing in Medpace (MEDP): Read This Before Placing a Bet

According to the average brokerage recommendation (ABR), one should invest in Medpace (MEDP). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Quest Diagnostics (DGX) Inks Deal to Acquire PathAI Diagnostics

Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.

IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed

IDEXX (IDXX) delivers better-than-expected earnings in the first quarter of 2024.